Publications

Publications

2023 International on Alzheimer's and Parkinson's Disease and Related Neurological Disorders (AD / PD) Conference

March 28 – April 2, 2023 | Gothenburg, Sweden

Effect of NE3107 on the Pharmacokinetics Profile of Carbidopa/Levodopa in Patients With Parkinson’s Disease: A Phase 2, Double-Blind, Placebo-Controlled Study

Safety, Tolerability, and Efficacy of NE3107 From a Phase 2, Double-Blind, Placebo-Controlled Study in Levodopa/Carbidopa-Treated Patients With Parkinson’s Disease

2022 Clinical Trials on Alzheimer's Disease (CTAD) Conference

November 29 – December 2, 2022 | San Francisco, California

Clinical Outcomes From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias

Biomarker Assessments From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias

Neuroimaging Data From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias